96
Views
0
CrossRef citations to date
0
Altmetric
Perspective

Avoiding research waste through cost-effectiveness analysis: the example of medication adherence-enhancing interventions

References

  • Sabate E. Adherence to long-term therapies: evidence for action. WHO, Geneva, Switzerland; 2003. Available from: www.who.int/chp/knowledge/publications/adherence_full_report.pdf [Last accessed 15 February 2014]
  • Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11(1):44-7
  • Gould E, Mitty E. Medication adherence is a partnership, medication compliance is not. Geriatr Nurs 2010;31(4):290-8
  • Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353(5):487-97
  • Oberjé EJ, de Kinderen RJ, Evers SM, et al. Cost effectiveness of medication adherence-enhancing interventions: a systematic review of trial-based economic evaluations. Pharmacoeconomics 2013;31(12):1155-68
  • Osterloh F. Medikamentöse Tabakentwöhnung: Weiterhin keine Kostenübernahme durch GKV. Dtsch Arztebl 2014;111(4):A-101/ B-89/ C-85
  • Cappelen AW, Norheim OF. Responsibility in health care: a liberal egalitarian approach. J Med Ethics 2005;31(8):476-80
  • Gandjour A. Investment in quality improvement: how to maximize the return. Health Econ 2010;19(1):31-42
  • Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998;18(2 Suppl):S68-80
  • Schlaiffer R. Probability and statistics for business decisions. McGraw-Hill; NY, USA: 1959
  • Vohra ND. Quantitative techniques in management. Tata McGraw-Hill; New Delhi, India: 2007. p. 924
  • Gandjour A. A model to predict the cost-effectiveness of disease management programs. Health Econ 2010;19(6):697-715
  • Gandjour A. Validation of models that estimate the cost-effectiveness of improving patient adherence. Value Health 2013;16(8):1170-1
  • Adarkwah CC, Gandjour A. Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany. Int J Technol Assess Health Care 2010;26(1):62-70
  • Neumann PJ, Sandberg EA, Bell CM, et al. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff 2000;19(2):92-109
  • Wells KJ, Battaglia TA, Dudley DJ, Patient Navigation Research Program. Patient navigation: state of the art or is it science? Cancer 2008;113(8):1999-2010

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.